IMMUNOTHERAPEUTIC FORMULATIONS TO GENERATE AUTOANTIBODIES CAPABLE TO AVOID THE BINDING OF INTERLEUKIN-2 TO ITS RECEPTOR.THEIR USE IN THE TREATMENT OF CANCER
THE PRESENT INVENTION IS RELATED TO PHARMACEUTICAL COMPOSITIONS BASED ON VACCINES AND MONOCLONAL ANTIBODIES THAT NEUTRALIZE THE INTERLEUKIN-2, WHICH ARE USEFUL IN THE TREATMENT OF TUMORS. PARTICULARLY THE PRESENT INVENTION IS RELATED TO THERAPEUTIC FORMULATIONS ABLE TO INCREASE THE IMMUNOGENICITY OF...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English |
Published |
31.05.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | THE PRESENT INVENTION IS RELATED TO PHARMACEUTICAL COMPOSITIONS BASED ON VACCINES AND MONOCLONAL ANTIBODIES THAT NEUTRALIZE THE INTERLEUKIN-2, WHICH ARE USEFUL IN THE TREATMENT OF TUMORS. PARTICULARLY THE PRESENT INVENTION IS RELATED TO THERAPEUTIC FORMULATIONS ABLE TO INCREASE THE IMMUNOGENICITY OF THE IL-2 CONJUGATED TO THE CARRIER PROTEIN P64K FROM THE NEISSERIA MENINGIFIDIS IN MONTANIDE ISA 51 ADJUVANT FOR THE INDUCTION OF IL-2 NEUTRALIZING AUTOANTIBODIES AND THE EFFECTIVE METHODS FOR THE TREATMENT OF TUMORS, INCLUDING BREAST CANCER. FURTHERMORE, THE PRESENT INVENTION IS RELATED TO THERAPEUTIC COMBINATION OF THE IL-2 BASED VACCINE WITH OTHER CANCER VACCINES BASED ON SPECIFIC TUMOR ANTIGENS OR TUMOR GROWTH FACTORS, AS WELL AS CHEMOTHERAPEUTICS AGENTS OR RADIOTHERAPY OF STANDARD USE FOR CANCER TREATMENT. |
---|---|
Bibliography: | Application Number: MY2005PI05353 |